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emDespite the global burden of cardiovascular disease, investment in cardiovascular drug development has stagnated over
the past 2 decades, with relative underinvestment compared with other therapeutic areas. The reasons for this trend are
multifactorial, but of primary concern is the high cost of conducting cardiovascular outcome trials in the current regu-
latory environment that demands a direct assessment of risks and beneﬁts, using clinically-evident cardiovascular end-
points. To work toward consensus on improving the environment for cardiovascular drug development, stakeholders
from academia, industry, regulatory bodies, and government agencies convened for a think tank meeting in July 2014 in
Washington, DC. This paper summarizes the proceedings of the meeting and aims to delineate the current adverse trends
in cardiovascular drug development, understand the key issues that underlie these trends within the context of a
recognized need for a rigorous regulatory review process, and provide potential solutions to the problems identiﬁed.
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1568D espite signiﬁcant improvements incardiovascular mortality over thelast several decades, cardiovascu-
lar disease remains the leading cause of death
both in the United States and the rest of the
world (1–3). Heart disease and stroke will
result in an estimated 24 million deaths/yearworldwide by 2030, and will continue to represent
the dominant cause of death among themost prevalent
chronic diseases (4–6) (Figure 1). Furthermore, mortal-
ity and morbidity due to cardiovascular events
continue to climb globally as a result of rising cardio-
vascular disease rates in low-income countries, result-
ing in increasing disparities in outcomes as a function
of wealth and education (7). The burden of cardiovas-
cular disease clearly remains both a major public
health concern and growing global challenge.
Notwithstanding this increase in cardiovascular
disease prevalence worldwide, investment in cardio-
vascular drug development has stagnated over the past
2 decades, with relative underinvestment compared
with other therapeutic areas (8–13). This alarming
trend appears to reﬂect the business strategy in the
pharmaceutical industry of maximizing return on in-
vestment (ROI) by focusing on areas currently felt to be
most lucrative (8,9). As discussed in the following text,
the reasons for these trends are multifactorial. How-
ever, a particularly important factor is the high cost
of conducting cardiovascular outcome trials in the
current regulatory environment that demands a direct
assessment of risks and beneﬁts using clinically-
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received January 28, 2015; accepted March 3, 2015.evident cardiovascular endpoints for approval rather
than biomarkers or putative surrogates. These realities
suggest that although the cardiovascular disease
burden continues to grow and innovative scientiﬁc
discoveries continue to occur, investors have concerns
regardingwhat they describe as regulatory uncertainty
and high development costs, leading to negative
effects on ROI for novel cardiovascular therapies.
To work toward consensus on improving the
environment for cardiovascular drug development,
stakeholders from academia, industry, and govern-
ment convened in July 2014 in Washington, DC. This
paper summarizes the proceedings of this “think
tank” meeting, the speciﬁc aims of which were to:
1. Delineate the current adverse trends in cardiovas-
cular drug development;
2. Understand the key issues that underlie these
trends within the context of a rigorous regulatory
review process that is a key aspect of drug devel-
opment; and
3. Provide potential solutions to the problems identiﬁed.
CURRENT TRENDS IN
CARDIOVASCULAR DRUG DEVELOPMENT
Between 2000 and 2009, U.S. Food and Drug Admin-
istration (FDA) approvals for new cardiovascular drug
therapies declined by approximately 33% compared
with the prior decade (11). During the discus-
sions, FDA representatives reported parallel adverse
trends in investigational new drug applications to theis an employee of Amgen, Inc. Dr. Braunstein is an
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FIGURE 1 Global Burden of Disease: Chronic and Infectious Diseases 2002 to 2030
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AIDS ¼ acquired immune deﬁciency syndrome; CVD ¼ cardiovascular disease; HIV ¼ human
immunodeﬁciency virus. Reprinted with permission from Fuster et al. (4) and adapted with
permission from and Mathers and Loncar (6).
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1569Division of Cardiovascular and Renal Drugs for
new molecular entities (NMEs) seeking approval for
marketing (with no change in investigational new
drugs and a relative decline in new marketing appli-
cations), including NMEs for cardiovascular disease,
from 1991 to 2013 (personal communication, N.
Stockbridge, December 6, 2014) (Figure 2). Parallel
analyses that evaluated regulatory approvals for car-
diovascular therapies demonstrated a similar tempo-
ral decline, but showed that approvals in several other
therapeutic areas, including oncology, rose substan-
tially during the same time frame (11).
CARDIOVASCULAR DRUG DEVELOPMENT COMPARED
WITH OTHER THERAPEUTIC AREAS. The application
of genomic technologies, as well as systems biology
approaches, have collectively identiﬁed multiple
potential new cardiovascular drug targets, as well
as actual molecules with potential cardiovascular
applications. Unfortunately, these scientiﬁc ad-
vances have not stimulated an increase in new car-
diovascular drug development. Early-phase research
and development appear to have stagnated, with
fewer molecules in the cardiovascular research pipe-
line compared with other therapeutic areas. In an
analysis comparing the number of drugs undergoing
early-phase development at 2 separate intervals (1990
to 1999 vs. 2000 to 2007), the development of anti-
neoplastic agents grew from 16.55% to 23.43%
(þ6.88%), whereas the development of cardiovascu-
lar agents experienced the strongest contraction of
any therapeutic area (–4.57%) (9). Furthermore, the
success rate for antineoplastic drug approvals
increased during this time interval (10). An analysis of
all FDA NMEs from 2000 to 2012 found that oncology
drugs had not only the greatest number of NME ap-
plications (n ¼ 61), but also the highest rate of ﬁrst-
cycle FDA approvals of all therapeutic classes (72%)
(12). In contrast, cardiovascular drugs had signiﬁ-
cantly fewer NME applications (n ¼ 21) and a much
lower rate of ﬁrst-cycle approvals (32%). The current
portfolio of drugs being evaluated in clinical trials
reﬂects these trends, with a steep rise in cancer drugs
being tested over the last 2 decades (Figure 3) (13).
RISING DRUG-DEVELOPMENT COSTS AND THE CONCEPT
OF REGULATORY UNCERTAINTY. Notwithstanding the
issues that appear to be impeding cardiovascular drug
development, during the last decades, the overall
pharmaceutical research and development processes
have become less efﬁcient in converting promising
therapies into actual approved and marketed agents
(Figure 4) (14). In 2005, the average capitalized cost to
bring 1 new biopharmaceutical product to market,
including the cost of failures, was $1.24 billion (14).
These high drug-development costs caused overallresearch and development spending to exceed $50
billion in the United States in 2008.
The high costs of drug development were consid-
ered by meeting participants to include the perceived
complexities and obstacles in navigating the regula-
tory drug approval process. Although the critical role
of the FDA and other regulatory agencies to balance
the timely approval of effective therapies with the
need to protect the public from harmful drugs was
discussed and strongly endorsed, the concept of
“regulatory uncertainty” appears to be deep-seated in
the pharmaceutical industry.
The pathway for drug development is becoming
more complex and costly for industry, but given mul-
tiple prior instances of drugs receiving regu-
latory approval that eventually resulted in patient
harm through post-market analyses, there is intense
government and public scrutiny on the regulatory drug
approval process (15). Nonetheless, the reality is that
the pharmaceutical industry will always be the domi-
nant funding source for drug discovery—a ﬁnding
reinforced by recent analyses that found that between
40% to 80% (16,17) of randomized controlled trials
published in top-tier medical journals were funded by
industry sponsors. Pharmaceutical representatives at
the meeting cited regulatory uncertainty as not only a
common concern across industries (18,19), but also a
key inﬂuence on decisions regarding the speciﬁc
development of innovative cardiovascular drugs
given the high cost of regulatory failures during drug
discovery. Despite these concerns, the FDA represen-
tatives expressed a strong willingness to meet early
with industry representatives to discuss plans for a
FIGURE 2 Marketing Applications for New Uses and NMEs and Research and Commercial IND Applications Received by the FDA by Year
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1570drug-development program to provide guidance and
feedback regarding the potential regulatory pathways
for a promising therapy before the launch of pivotal
registration trials.
Studies in economics and ﬁnance have found regula-
tory uncertainty to be potentially a major source of un-
predictable variation in the return on business
investment (20). The regulatory state is oftenperceived as
a key component of the “external environment” that
pharmaceutical companies must take into account when
making capital investments or deciding whether to enter
competitive markets (18). Some therapies may follow aive Compounds Between Phase I and III Development Over Time
fectives (including vaccines)
vascular
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sion from Berggren et al. (13).known regulatory pathway, whichmay decrease the time
to drug approval. For other therapies, the pathway for
regulatory approval has not been deﬁned or has been
inﬂuenced by prior regulatory decisions for therapies in a
similar class, so the timeline for drug approval may be
expected to be prolonged or difﬁcult to predict. The FDA
also recognizes that although innovative drugs are more
difﬁcult and costly to develop, they may also be more
difﬁcult to review given the lack of experiencewith a new
therapy or indication (21). Thus, although regulatory un-
certainty may be a key factor inﬂuencing the trends in
cardiovascular drug development, the path forward may
involve early, in-depth discussions with industry repre-
sentatives and regulatory agencies that would be ex-
pected to guide decisions about how to structure a
development program that addresses an unmet need in
clinical practice, but also appears viable within the
context of a rigorous but fair regulatory review process.
REGULATORY ISSUES ASSOCIATED WITH THE
GLOBALIZATION OF CLINICAL TRIALS. From a
contemporary United States perspective, the
globalization of cardiovascular clinical trials has
resulted in increased regulatory complexity at both
the FDA and European Medicines Agency (EMA) (22).
Although recent efforts have been made to stan-
dardize regulatory reporting in Europe (23), the EMA
remains a decentralized organization, with each Eu-
ropean nation still having its own drug agency and
regulations. Because cardiovascular drug registration
FIGURE 4 New Drug Approvals and Pharmaceutical R&D Expenditures in the
United States From 1963 to 2008
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1571trials typically involve many countries to meet
enrollment goals, a large and experienced pool of
cardiovascular site investigators is critical to the
success of these trials. However, over the past
decade, the number of FDA-regulated investigators
based outside of the United States has grown by 15%
annually, whereas United States–based investigators
have declined 5.5% annually over the same interval
(24). Nonetheless, studies have shown that the FDA
approves drugs faster than the EMA and Health Can-
ada (median: 303, 366, and 352 days, respectively)
(25), but enrollment in cardiovascular registration
trials has appeared to shift to non-Western countries
with perceived greater enrollment potential and
lower operational costs. Although difﬁculty in patient
recruitment has contributed to this shift of trial
enrollment to non-Western countries (26), the
perceived bureaucratic and expensive regulatory en-
vironments in Western countries is another strong
inﬂuence (22).
Although globalization of trial conduct and enroll-
ment could theoretically reduce upfront costs for
pivotal registration trials, growing concern exists over
the geographical variation in patient selection and
results in cardiovascular outcomes trials (27,28). The
recent TOPCAT (Treatment of Preserved Cardiac
Function Heart Failure with an Aldosterone Antago-
nist) trial demonstrated clear differences in patient
selection for heart failure with preserved ejection
fraction amongst patients in Russia and Georgia,
which highly confounded the overall trial results (29).
Additionally, low enrollment of patients in the United
States in pivotal registration trials can also introduce
confounding, as was demonstrated in the PLATO
(Study of Platelet Inhibition and Patient Outcomes)
trial with the antiplatelet agent ticagrelor (30). The
treatment results were discordant in the United States
compared with other geographic regions, with <10%
of the patients enrolled in the United States. There-
fore, the globalization of clinical trials appears to
contribute to regulatory uncertainty and to complicate
the regulatory review process for therapies with
pivotal trials that showed geographical differences in
patient selection/features as well as treatment results.
POTENTIAL CAUSES OF
RELATIVE UNDERINVESTMENT IN
CARDIOVASCULAR DRUG DEVELOPMENT
FEW INCENTIVES TO PROMOTE CARDIOVASCULAR
DRUG DEVELOPMENT. Cardiovascular drug devel-
opment currently suffers from a lack of “push-pull”
incentives relative to other ﬁelds, particularly on-
cology, which tends to dominate contemporary drugdevelopment. “Push” funding policies aim to incen-
tivize the pharmaceutical industry by reducing costs
during the research and development stages, whereas
“pull” mechanisms create incentives for the phar-
maceutical industry by creating viable market de-
mand for novel therapies that address unmet clinical
needs (31). Push mechanisms may partially offset
research and development by underwriting a portion
of the costs, whereas pull mechanisms may reward
positive trial results for novel therapies.
At the federal funding level, the ﬁeld of oncology
has several push mechanisms that may accelerate the
discovery of novel therapies by academic researchers
that could potentially be commercialized through
academic-industry collaborations. First, the 2013
National Institutes of Health (NIH) budget was
approximately $29.3 billion, with $4.8 billion allo-
cated to the National Cancer Institute (NCI), the
largest proportion among all institutes and a distinc-
tion held by the NCI since at least 1980 (32,33). In
comparison, despite the relative proportional in-
crease in the budget of the National Heart, Lung, and
Blood Institute (NHLBI) compared with the NCI dur-
ing this time period (32), the allocation in the 2013
budget to the NHLBI was signiﬁcantly lower at $2.9
billion (34). Second, the FDA has several special-
designation programs designed to expedite and
facilitate the authorization and approval of new
medications for unmet medical needs. A detailed
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1572analysis found that the greatest percentage of appli-
cations to each of these programs was for oncology
therapies (35). In comparison with oncology drugs,
cardiovascular drug applications were far fewer in all
programs: orphan (9% vs. 38%), priority review (4%
vs. 53%), accelerated approval (8% vs. 32%), and fast
track (1% vs. 56%). Finally, as a result of the FDA’s
orphan program and the increasing focus of the
pharmaceutical industry on novel “ﬁrst-in-class”
therapies, the number of NMEs targeting orphan in-
dications has risen 3-fold over the past 3 decades (36).
However, there are few cardiovascular disease con-
ditions that would qualify for orphan drug programs,
so the interest for novel therapies has naturally shif-
ted to the oncology ﬁeld.
Advocacy and fundraising, major push mecha-
nisms, are also dominated by oncology. In 2011, char-
itable donations raised during the Susan G. Komen
Race for the Cure for breast cancer ($258 million) and
Movember for prostate cancer ($147 million) were over
7-fold greater than that of the American Heart Asso-
ciation (AHA) Jump Rope for Heart campaign
($54 million) (37). Furthermore, the AHA raised $509
million in 2010, compared with $903 million raised
by the American Cancer Society (38). The oncology
ﬁeld has also dominated crowdfunding initiatives—
ventures that raise small amounts of money from a
large number of people (typically via the Internet).
A recent analysis of 97 crowdfunding campaigns
aimed at cancer research found that the average
amount raised per campaign was $45,629 (average
donation: $186), including 5 rare-disease campaigns
raising between $17,217 and $248,734 (39). In contrast,
few crowdfunding campaigns have involved cardio-
vascular disease, although a new initiative to fund
early-stage products was introduced at the AHA 2014
Scientiﬁc Sessions (40). Finally, an example of the
consequences of philanthropic discrepancies affecting
future drug development is reﬂected in the number of
young investigator awards available for fellows in
either subspecialty: the AHA had 0 research grants of
at least 1 year in duration for fellows in 2012, the
American College of Cardiology had 4, and the Amer-
ican Society of Clinical Oncology had 38 (41).
What drives successful cancer fundraising cam-
paigns? It is possible that certain organizations are
better organized to raise funds. However, fear may
also explain the documented discrepancy between
public perception of disease severity and reality (42).
For example, a 2011 survey conducted by the MetLife
Foundation found that 41% of responders named
cancer as the disease they fearedmost; only 8% named
heart disease, and another 8% feared stroke (43).
Surveys of women conducted by the AHA show manybelieve cancer to be the number 1 cause of death for
females, not heart disease, as annual mortality statis-
tics consistently conﬁrm (44). Given that the diagnosis
of cancer typically elicits a much greater emotional
response than that of cardiovascular disease, the dis-
parities in the breadth and success of fundraising and
advocacy campaigns for cancer versus cardiovascular
disease likely reﬂect societal opinions on the “unmet
needs” for medical conditions, despite the aforemen-
tioned global burden of cardiovascular disease.
DIVERTING INVESTMENT AWAY FROM CARDIO-
VASCULAR THERAPIES. Even though the biotech-
nology sector continues to show interest in drug
development, trends for venture capital funding pri-
orities demonstrate a shift away from cardiovas-
cular disease. Between January 2005 and June 2012,
acquisitions of venture-backed life science com-
panies with 1 or 2 products in the pipeline remained
strong (45). However, companies with oncology and
infectious disease products had the greatest acquisi-
tions, with approximately double the money spent
compared with acquisitions that focused on cardio-
vascular disease products. Similarly, biotechnology
companies with either an oncology or a neurology
focus had the most licensing agreements during the
same time period (2005 to 2012)—4-fold higher than
the cardiovascular arena. The consensus opinion
expressed at the meeting was that although it appears
that venture capital investor interest in biotech-
nology remains strong, the appetite for risk is lower
compared with historical trends, so investment ﬁrms
typically are less interested in cardiovascular drug-
development programs given the uncertain ROI for
the previously mentioned reasons. Compared with
the blockbuster therapies that were previously de-
veloped from biotechnology companies, investors are
now prepared to accept a lower ROI (i.e., an orphan
drug for a deﬁned and small population) in exchange
for a lower risk of drug-development failure (46,47).
In fact, global sales of oncology drugs in 2013 topped
$67 billion, the highest of any class of medications
(48). These ﬁndings highlight the interest of invest-
ment ﬁrms in oncology therapies that typically have a
clear regulatory pathway and a strong degree of
advocacy from patient groups.
COMMERCIAL VIABILITY OVER EFFICACY OR SAFETY AS
A DRIVER OF CARDIOVASCULAR DRUG-DEVELOPMENT
FAILURE. In addition to a lack of push incentives, a
lack of pull incentives currently hinders cardiovascu-
lar drug development due mainly to industry concerns
regarding ROIs. A recent analysis demonstrated that
cardiovascular drug failures following pivotal regis-
tration trials most often result from a lack of com-
mercial viability rather than from efﬁcacy or safety
FIGURE 5 Drug Failures by Therapeutic Class, 2000 to 2009
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1573issues (10) (Figure 5). Failure from commercial
viability for cardiovascular therapies occurred for
several reasons, including cases where expected
future costs rise or expected revenues fall (perhaps
due to increased competition or that testing suggests
the target proﬁle should be narrowed) to the point
where the project is no longer perceived to
be ﬁnancially viable, or when pharmaceutical ﬁrms
abandon a development program for strategic rea-
sons (J.A. DiMasi, personal communication, December
9, 2014). For cardiovascular therapies, physicians,
payers, and regulatory agencies demand large trials
that are adequately powered to show a difference in
clinical outcomes for approval. In general, and apart
from some conditions such as heart failure, the pro-
gression of cardiovascular disease to “hard” natural
history outcomes is relatively prolonged compared
with the more rapid accumulations of such outcomes
in oncology. Therefore, cardiovascular outcomes tri-
als require large sample sizes and must continue for
many years to accumulate enough endpoints to be
adequately powered. Additionally, new cardiovascu-
lar medications must be tested on a background of a
multitude of guideline-recommended therapies that
comprise the “standard of care.” Because patients
selected for most cardiovascular outcomes trials on
background medical therapy have relatively low event
rates, trials have become larger, prolonged, and cost-
lier with each new therapeutic modality (49).
NECESSITY OF MEASURING VALIDATED CLINICAL
OUTCOMES OVER SURROGATE ENDPOINTS. The use
of putative surrogate endpoints to bring potentially
beneﬁcial treatments to patients many years before
the availability of clinical outcomes at relatively
lower cost appeals to investors, scientists, and pa-
tients who hope to seek access to beneﬁcial therapies
(50). Yet, such shortcuts can have several well-
documented unintended consequences, demanding
direct measures of clinical outcomes that matter to
patients. In cardiovascular medicine, both blood
pressure and low-density lipoprotein levels have
served as surrogates of important clinical outcomes
under speciﬁc circumstances, but only after valida-
tion in multiple randomized clinical trials involving
tens of thousands of patients (51,52). Success of the
IMPROVE-IT (Improved Reduction of Outcomes:
Vytorin Efﬁcacy International Trial), which demon-
strated that low-density lipoprotein lowering with a
combination of ezetimibe and simvastatin versus
simvastatin alone resulted in improved long-term
clinical outcomes, provides further impetus for the
development of novel agents, including PCSK9 in-
hibitors (53). Yet, alpha-adrenergic blockers lower
blood pressure but appear to be inferior in reducingcardiovascular events compared with other blood
pressure-lowering treatments (54). Torcetrapib and
long-acting niacin increased high-density lipoprotein
cholesterol considerably, but provided no cardiovas-
cular outcome beneﬁts in multiple large trials and,
conversely, were associated with signiﬁcant harm
due to off-target drug effects (55,56). Other cardio-
vascular clinical trials have exposed harms after
showing positive results with surrogate outcomes,
including morbidity from the utilization of inotropes
in cardiogenic shock despite improved hemody-
namic parameters or death associated with the use of
class IC antiarrhythmic agents despite successful
suppression of premature ventricular contractions
post-myocardial infarction (57–59).
Intermediate endpoints, such as progression-free
survival (PFS), are more commonly used in oncology.
The use of PFS among all systemic-therapy random-
ized controlled trials of breast, colorectal, and non–
small-cell lung cancers published in the Journal of
Clinical Oncology increased from 0% (1975 to 1984) to
26%more recently (2005 to 2009), whereas 23% of new
FDA drug approval indications from 2005 to 2007 were
on the basis of trials with PFS as the primary endpoint
(60–62). Therefore, there has not only been a clear
increase in the use of intermediate endpoints over
time, but the prevalence of intermediate endpoint use
has been consistent across studies. Justiﬁcation for
the use of PFS as a valid outcome for drug approval
relates to the extended patient follow-up and to being
confounded by causes of mortality unrelated to can-
cer. Furthermore, as novel therapies demonstrate
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cancers such as breast and colorectal, survival may be
inﬂuenced by the use of such therapies when trials
have been completed (63,64). However, the use of PFS
as a primary endpoint in many randomized controlled
trials of advanced solid tumors, including breast can-
cer, has not been on the basis of evidence of its sur-
rogacy for either overall survival or quality of life
(60,65). Despite approving many therapies on the ba-
sis of PFS, the FDA has long acknowledged that tumor
responses may not necessarily equate with clinical
beneﬁt, because nonresponding patients may beneﬁt
from a delay in tumor progression and tumors may
recur more aggressively if they regress quickly in some
cases (66,67). Taken together, despite their appeal to
make trials more efﬁcient, putative surrogate end-
points do not fully predict the true balance of risk and
beneﬁt of interventions. This failure usually is a result
of incomplete coupling between the biomarker of
interest and the array of clinical outcomes and the
unknown and unintended pharmacological actions of
an intervention that are independent of the disease
process (68).
Notwithstanding the different types of outcomes
that meet the thresholds for approval in cardiovas-
cular disease versus cancer, the quality of clinical trial
evidence used for recent approvals of novel thera-
peutic agents varies widely across indications. An
analysis of the pivotal clinical trial evidence required
for FDA approval between 2005 and 2012 is striking:
cardiovascular disease, diabetes mellitus, and hy-
perlipidemia trials were larger than those in other
therapeutic areas (median sample size ¼ 651 sub-
jects), were of longer duration (median ¼ 24 weeks),
were mostly randomized (98.6%), were typicallyTABLE 1 Design of Pivotal Efﬁcacy Trials Providing the Basis for App
2005 and 2012, Stratiﬁed by Therapeutic Agent
Therapeutic Agent
(Pivotal Trials) Patients Duration, Weeks
CVD, DM, hyperlipidemia
(n ¼ 72)
651 (406–926) 24.0 (10.0–26.0)
Cancer
(n ¼ 55)
266 (84–610) 18.5 (8.9–29.2)
Infectious disease
(n ¼ 57)
585 (319–697) 5.0 (2.5–24.0)
Neurology
(n ¼ 38)
358 (234–613) 16.0 (12.0–21.0)
Dermatology
(n ¼ 29)
233 (121–491) 4.3 (2.0–13.0)
Autoimmune/MSK
(n ¼ 36)
525 (362–749) 24.0 (24.0–28.0)
Psychiatry
(n ¼ 43)
432 (275–590) 6.0 (6.0–8.0)
Values are median (interquartile range) or %. Adapted with permission from Downing e
CVD ¼ cardiovascular disease; DM ¼ diabetes mellitus; MSK ¼ musculoskeletal.conducted in a double-blind fashion (93.2%), and
almost uniformly used a placebo or an active control
in the comparator arm (97.2%) (Table 1) (69). In
contrast, trials used to support cancer drug approvals
were small (median sample size ¼ 266 subjects), were
of shorter duration (median ¼ 18.5 weeks), were less
frequently randomized (47.3%), were less frequently
conducted in a double-blind manner (27.3%), and less
than one-half used a placebo or active control in the
comparator arm (47.3%). The consensus at the
meeting was that cardiovascular medicine must
continue to rely on proven clinical outcomes in the
new era of drug development, especially in light of
the previously-mentioned failures of putative surro-
gate endpoints (54–59).
“MISCLASSIFICATION” OF CARDIOVASCULAR DISEASE:
IMPLICATIONS FOR DRUG DISCOVERY. Traditionally,
cardiovascular drug development has focused on
systemic therapies centering on large populations,
such as hypertension and heart failure. However,
these conditions result from multiple heterogeneous
inﬂuences and pathways and have several potential
therapeutic biological targets. Relatively few new
drug targets for cardiovascular disease exist that can
be completely separated from potential overlap with
existing targets, because there are often multiple
effective drugs in any given class (i.e., statins, anti-
platelet agents, novel anticoagulants), which often
renders distinction from existing therapies difﬁcult.
This setting presents considerable challenges to the
development of new therapies. Yet, recent scientiﬁc
advances, including harnessing genetic and systems
biology approaches, promise to yield many novel
drug targets in the multiple pathways involved in
cardiovascular diseases such as thrombosis,roval of Novel Therapeutic Agents by the FDA Between
Randomized Double-Blinded
Placebo or Active-Control
Comparator
98.6 93.2 97.2
47.3 27.3 47.3
93.0 78.9 91.2
100.0 100.0 94.7
93.1 75.9 86.2
100.0 94.4 100.0
100.0 100.0 100.0
t al. (69).
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1575myocardial relaxation and strain, lipid metabolism,
and atherosclerosis. The traditional “lumping” of
heterogeneous disease—on the basis of taxonomy
established by the International Classiﬁcation of
Diseases that seldom incorporated rapidly-emerging
molecular data, incidental patient characteristics, or
socio-environmental inﬂuences on disease (70)—
should give way to a subclassiﬁcation on the basis of
biological signatures that better represents the un-
derlying pathophysiology and permits more precise
targeting of treatments (71). This approach mimics the
now well-established strategy of targeted therapies in
oncology (receptor level) and infectious diseases
(organism level) and provides enticing drug targets.
As opposed to cancers, common cardiovascular dis-
eases do not arise from single gene mutations, but
rather reﬂect interactions of risk factors with multiple
genes that each contribute a small portion of risk.
This complexity currently furnishes fewer appealing
biological targets in cardiovascular medicine than in
cancers (9). Nonetheless, in a recent industry survey,
most large pharmaceutical companies (14 of 16) have
still expressed an interest in partnering regarding
cardiovascular disease (44).
STRATEGIES TO ADVANCE
CARDIOVASCULAR DRUG DEVELOPMENT
REDUCE OPERATING COSTS OF CLINICAL TRIALS.
Well-intentioned efforts to minimize the risk of harm
or undesirable outcomes in patients enrolled in clin-
ical trials have introduced numerous inefﬁciencies in
the conduct of trials, particularly in pivotal registra-
tion trials that result in rigorous regulatory review
(72). Meeting participants uniformly agreed that
reducing the amount of extraneous data collected for
a cardiovascular clinical trial offers an important cost
savings opportunity. The typical clinical trial in 2012
involved 13 endpoints, had 169 case report form
pages, and required study volunteers to make 11 visits
over an average of 175 days (49). To advance discus-
sions about reducing the amount of extraneous data
collected for a large cardiovascular outcomes trial,
the participants recommended that pharmaceutical
industry sponsors meet early with key stakeholders
(regulators, academic collaborators) to omit collec-
tion of unessential data and to simplify case report
forms. Furthermore, there was a clear recommenda-
tion from FDA representatives to the pharmaceutical
industry to meet with the FDA to gain a commitment
early during the drug-development process to limit
the amount of data to be collected. Academic
collaborators should be encouraged to support the
scientiﬁc legitimacy of this approach, with the goalof emphasizing quality by design (discussed in the
following text). Adopting FDA guidance with respect
to centralized monitoring practices and risk-based
monitoring is a strategy that should continue to
ensure subject protection and overall study quality
while increasing efﬁciency (73). Other strategies to
reduce costs include the use of centralized institu-
tional review boards (74,75) and improving the sys-
tem of reporting and interpreting unexpected serious
adverse events through decreasing the review of un-
interpretable case reports (76). The Clinical Trials
Transformation Initiative (CTTI)—a public-private
partnership founded by the FDA and Duke Univer-
sity to identify barriers to the conduct of large, simple
trials—has recognized other important impediments
to clinical research involving regulatory bodies,
sponsor-imposed delays, academic impediments, and
health system and clinical practice site impediments
(72). Finally, harnessing the massive National Patient-
Centered Clinical Research Network (PCORnet) pro-
gram to centralize and organize clinical data will not
only augment our understanding of risk and out-
comes for people with speciﬁc diseases, but should
also provide answers that are vital to patients more
quickly, efﬁciently, and at a lower cost than previ-
ously possible (77).
INCREASE FOCUS ON PRACTICAL, STREAMLINED
TRIALS. Despite a temptation to use surrogate end-
points to decrease sample sizes and shorten the
duration of clinical trials (ostensibly to reduce the
likelihood of drug-development failures), it was
agreed that we must continue to promote large,
pragmatic trials to measure clinical outcomes when
evaluating new cardiovascular therapies. Larger trials
also help resolve conﬂicting data. After post-approval
analyses of data from small, randomized trials sug-
gested that use of nesiritide was associated with a
rate of worsening renal function and death, the
ASCEND-HF (Acute Study of Clinical Effectiveness of
Nesiritide in Decompensated Heart Failure) demon-
strated the safety of nesiritide but demonstrated no
efﬁcacy beneﬁts with this agent (78). Finally, if con-
ducted properly, large, simple trials can prove to
be successful despite high rates of background,
guidelines-recommended therapies that are known to
improve outcomes when used widely. A prime ex-
ample of the contemporary success of a novel agent
studied in a large trial is PARADIGM-HF (Prospective
Comparison of ARNI [Angiotensin Receptor–Neprilysin
Inhibitor] with ACEI [Angiotensin-Converting–Enzyme
Inhibitor] to Determine Impact on Global Mortality and
Morbidity in Heart Failure Trial), which compared
LCZ696 versus enalapril in heart failure with reduced
ejection fraction (79). This trial was stopped early due
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quality by design principles during the planning of
large, simple trials is a key ingredient for trial
streamlining. CTTI promotes quality by design
with the goal that clinical trials will be more stream-
lined, ﬁt for purpose, and quality driven (80). Trials
with adequate sample sizes to assess beneﬁts and
risks using cardiovascular events should, therefore,
remain the reference standard for cardiovascular
drug development.
LEVERAGE PHASE II TRIALS TO INFORM PHASE III
TRIALS. Many participants in the meeting felt that the
research and development community could more
effectively leverage data collected from phase II trials
to better plan for phase III trials. Although there is a
need to use phase II trial data to predict phase III
outcomes and to adequately design phase III trials for
regulatory approval, it is equally important to use the
data gathered to understand the impact of a novel
therapy on biology and disease pathways to plan
future development. Phase II studies should, thus,
focus on informing and reﬁning important vari-
ables such as dosing, population pharmacokinetic
modeling, side effects, and the treatment effect on
biomarkers before commencing pivotal phase III
registration trials. In fact, biomarkers are most ap-
propriately used in phase II trials to screen for prom-
ising new therapies through evaluation of biological
activity (68). Embedding adaptive design (AD) within
a single clinical trial may furnish a novel strategy as
well. This approach allows a review of accumulating
information during a trial that may suggest modiﬁca-
tion of trial characteristics, thus addressing uncer-
tainty about choices made during planning (81). AD
allows pre-speciﬁed updates to the maximum sample
size, study duration, treatment group allocation,
dosing, number of treatment arms, or study end-
points. AD could translate into more efﬁcient therapy
development by reducing trial size. In turn, this could
lead to more viable studies, with less risk for sponsors.
However, although some academic and industry rep-
resentatives may be eager to use AD strategies, regu-
lators have been rightfully cautious to accept all AD
trials for approval due to the broad spectrum of
potentially problematic adaptations involved (81,82).
USE NOVEL NIH PROGRAMS TO SUPPORT EARLY-
PHASE DEVELOPMENT. Despite pre-clinical testing
and selection, many drugs that enter human studies
never make it to market because of failure between
phases I and III (83). The NIH has initiated new pro-
grams in search of an effective approach to actively
support early clinical development, hoping to provide
a bridge to facilitate successful innovation. Althoughthe majority of NIH funding goes to support non-
human research, it is also committed to funding
applied sciences (84). The newest NIH institute, the
National Center for Advancing Translational Sciences,
was created in 2010 to accelerate translation of
ideas into treatments via different programs, in-
cluding those that enable repurposing of existing
drugs for new indications (85).
The NHLBI has also developed several new ap-
proaches to speciﬁcally facilitate the translation of
basic cardiovascular discoveries into clinical applica-
tions. The goal is to continue to develop a variety of
programs that create teams of academic investigators
and industry partners (86) (Figure 6). The NIH Centers
for Accelerated Innovations (NCAIs) aim to identify
and advance the development of promising emerging
technologies toward new commercial products for the
prevention and management of medical conditions
affecting the cardiovascular, pulmonary, and hema-
tologic systems. The NCAIs are developing a central-
ized institutional approach to move basic science
discoveries through the early stages of technology
development to enable their subsequent commer-
cialization. Inventors, especially those who are new
to the product-development process, have access to
relevant personal training and mentoring opportu-
nities. The new Vascular Interventions/Innovations
and Therapeutic Advances program (87) aims to
address the need for new or better therapeutic in-
terventions (drugs or devices) and diagnostic modal-
ities in several medical conditions that have been
traditionally neglected by industry. Strategies
include: 1) no restrictions on the applicant’s type of
institutional afﬁliation or on geographic location
(within the United States); 2) assistance with project
management, regulatory issues, and expert industry
advice; and 3) opportunities to leverage other exist-
ing NIH translational programs. Areas of recent
funding include vascular disorders, thrombotic dis-
eases, and pulmonary hypertension. The Small Busi-
ness Innovation Research funding mechanism
provides seed funding to support the development of
a broad array of commercial products to detect, di-
agnose, treat, and prevent disease. Other current
programs include the Science Moving Towards
Research Translation and Therapy program and the
Gene Therapy Research Program (GTRP). These new
programs are unproven, but they do represent an
effort by the NHLBI to encourage and enable cardio-
vascular drug research even in the risk-adverse capi-
tal environment that currently exists.
LEVERAGE ACADEMIC EXPERTS AS AN INTERFACE
BETWEEN INDUSTRY AND REGULATORY BODIES.
Optimal cardiovascular drug development depends on
FIGURE 6 NHLBI Programs That Exemplify the Opportunities Created to Support
Translation Using Funding or Assistance-Type Mechanisms
Adapted with permission from Galis et al. (87). GTRP ¼ Gene Therapy Resource Program;
NCAIs ¼ National Institutes of Health Centers for Accelerated Innovations; NHLBI ¼ Na-
tional Heart, Lung, and Blood Institute; SBIR ¼ Small Business Innovation Research;
SMARTT ¼ Science Moving Towards Research Translation and Therapy; VITA ¼ Vascular
Interventions/Innovations and Therapeutic Advances.
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1577true partnerships amongst academic representatives,
regulatory ofﬁcials, industry scientists, and clinical
researchers, as well as practicing clinicians—all of
whom represent the needs of patients with cardio-
vascular disease (Central Illustration). The use of aca-
demic clinical trialists is important in the design and
conduct of pivotal cardiovascular registration trials
where expertise on the cardiovascular disease condi-
tion, clinical trial operations, and established rela-
tionship with regulatory agencies are integrated
attributes that are unique to academic researchers
(88). Academic researchers can work with the phar-
maceutical industry to help identify and deﬁne unmet
clinical needs and to translate mechanisms of drug
effect into clinical scenarios where the beneﬁts may
exceed the risks. Those qualifying as academic re-
searchers are typically university-afﬁliated, have
expertise in the ﬁeld, and have prior clinical trial
experience. Selected academic research organizations,
especially in cardiovascular medicine, foster the “sci-
ence of clinical operations” and stand well-positioned
to enact and conduct efﬁcient and streamlined clinical
trials. However, academic clinical trials do not have to
be afﬁliated with an academic research organization.
Above all, with expertise and understanding of
clinical practice, academic researchers can facilitate
discussions between the regulatory bodies and the
pharmaceutical industry from the perspective of
expertise in disease therapeutics and patient-centered
clinical care.
CONTINUE TO STRENGTHEN THE SCIENCE. Many
cardiovascular drugs have been developed on the
basis of proven biological activity in modifying a
biomarker, hoping that the biomarker directly reﬂects
disease outcomes. As discussed previously, many
successful therapies have targeted biomarkers (spe-
ciﬁc lipid fractions and hypertension), resulting in
improved clinical outcomes, but the deﬁnitive
recommendation for therapy occurred only after
vigorous testing in the form of multiple clinical trials
with thousands of patients and valid clinical end-
points. In this setting, the effect sizes may be modest,
and therefore, interventions require large trials to
show beneﬁt. At the meeting, there was general
agreement that to improve efﬁciency from a scientiﬁc
standpoint, development strategy should move away
from targeting a directional change in biomarkers to:
1) use biomarkers to form enriched populations and
further classify disease; and 2) learn more about the
biologic targets and causal mechanisms that drive
most cardiovascular diseases.
Using biomarkers to enrich study populations may
help reﬁne our deﬁnitions of disease and lead to
successful drug development. Several examplesalready exist in the published data. In the COMPAN-
ION (Comparison of Medical Therapy, Pacing, and
Deﬁbrillation in Heart Failure) trial, which demon-
strated a 20% reduction in all-cause mortality
or hospitalization with treatment with chronic re-
synchronization therapy (with or without an intra-
cardiac deﬁbrillator), the patient population was
enriched by only including those with a QRS interval
of $120 ms. The investigators widely acknowledge
that if this therapy had been applied to the entire
heart failure population, it almost certainly would
have been negative (89). The JUPITER (Justiﬁcation
for the Use of Statins in Prevention: an Intervention
Trial Evaluating Rosuvastatin) primary prevention
trial, which demonstrated a reduction of major car-
diovascular events with rosuvastatin, enriched an ap-
parently healthy population by including only those
with an elevation of an inﬂammatory marker, C-reac-
tive protein (90). Finally, although the TOPCAT trial of
spironolactone in patients with preserved ejection
fractionwas negative overall, a pre-speciﬁed subgroup
of patients with elevated brain natriuretic peptide
may have beneﬁtted—a ﬁnding that must be regarded
as exploratory and requires replication (91). Enrich-
ment with biomarkers could help fuel studies to
tackle several unmet cardiovascular research needs,
CENTRAL ILLUSTRATION Goals of Stakeholders Involved in New Cardiovascular Drug Development and Their Inﬂuence on Each Other
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  Fordyce, C.B. et al. J Am Coll Cardiol. 2015; 65(15):1567–82.
Optimal drug development for patients with cardiovascular disease requires true partnerships among academic researchers, regulatory ofﬁcials, industry representa-
tives, government-funded researchers, and practicing clinicians.
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1578including pulmonary hypertension, hypertrophic car-
diomyopathy, and congenital heart disease. Therefore,
although the use of biomarkers as surrogate endpoints
can prove treacherous, they may be useful to enrich
populations that may beneﬁt from speciﬁc therapies.
To improve understanding of the causal mecha-
nisms of disease, several novel approaches have
been leveraged. A genome-wide association study
identiﬁed 13 new susceptibility loci for coronary ar-
tery disease (92). Of the 13 loci, only 3 were associated
with conventional, established cardiac risk factors,
and all were found to be of greater signiﬁcance than
PCSK9, which missed the genome-wide signiﬁcance
level by a small margin. This analysis shows that
there are many potential nonconventional targets
associated with the pathogenesis of coronary artery
disease available for mining. Next-generation sequ-
encing found a strong association between titin and
dilated cardiomyopathy (93), and the importance
of systems biology approaches for drug discovery
has now been recognized for over a decade (94).
Other strategies include Mendelian randomization,proteomics, and metabolomics. New basic science
technologies have helped further our understanding of
some of the causal mechanisms of cardiovascular dis-
ease and have the potential to stimulate future
drug development. Increasing transdisciplinary ex-
changes of knowledge between the basic and clinical
research ﬁelds through training and collaborationswill
enhance efforts to identify new targets, pathologic
mechanisms, and drugs to address the unmet need in
cardiovascular disease.
STRATEGIES TO IMPROVE INDUSTRY-SPONSORED
CARDIOVASCULAR DRUG DEVELOPMENT. The phar-
maceutical industry is generally composed of 2 main
industry groups: those from the top 15 largest phar-
maceutical companies (“Big Pharma”) and other
companies considered small to medium-sized enter-
prises (95). From a drug-development process, this
distinction may be important when evaluating re-
search and development strategies. Small to medium-
sized enterprises typically focus on the biology and
potentially large effect sizes in serious cardiovascular
illnesses. As discussed, leveraging human genetics or
TABLE 2 Key Issues Underlying Adverse Trends in Cardiovascular
Drug Development and Potential Solutions
Issue Solution
Rising costs  Reduce extraneous data collected
B Meet early with key stakeholders
(regulators, academic collaborators)
to set limits
B Adopt quality by design
B Implement centralized monitoring
practices/risk-based monitoring
B Prioritize the collection of suspected
unexpected serious adverse reactions;
limit collection of other adverse
events
 Centralize institutional review boards
 Harness PCORnet to help centralize and
organize clinical data
Regulatory uncertainty  Ensure frequent and early communica-
tion with regulators
 Leverage academic experts to interface
between industry and regulatory bodies
 Use NIH programs to mitigate ﬁnancial
risk in early phases
 Consider novel trial design
B Adaptive design
B Pre- and post-marketing approval
studies
Necessity of validated clinical
outcomes over surrogate
endpoints
 Increase focus on practical, streamlined
trials
B Adopt quality by design
B Use phase II to inform phase III:
dosing, pharmacokinetic modeling,
side effects, and biomarkers
 Use biomarkers to enrich populations,
but continue to demand clinical
outcomes
Apparent decline in new
cardiovascular drug targets
 Strengthen novel scientiﬁc methods to
further deﬁne the pathophysiology and
create new “biological signature”
B Genome-wide association studies
B Next-generation sequencing
B Mendelian randomization
B Proteomics and metabolomics
 Leverage NIH programs to facilitate
translation of basic cardiovascular dis-
coveries into clinical applications
Discord between cardiovascular
burden and public perception
 Channel advocacy through the American
Heart Association and American College
of Cardiology
NIH ¼ National Institutes of Health; PCORnet ¼ National Patient-Centered Clinical Research
Network.
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1579known human pharmacology will be extremely valu-
able to identify drug targets with a higher likelihood
of success, instead of investing in a multitude of
targets and accepting that some will fail. An example
of this was the identiﬁcation of the PCSK9 protein as a
compelling target to treat hypercholesterolemia
(96,97). The convergence of deoxyribonucleic acid
sequencing, computational biology, and statistical
methods is uncovering new compelling targets that
should lead to the next wave of therapies aimed at
reducing cardiovascular morbidity and mortality. In
addition, this new paradigm should mitigate invest-
ment risk and facilitate the acceleration of high-
potential programs. As a corollary, some meeting
participants felt that a move toward reduced invest-
ment in targets supported only by nonclinical genetics
and disease models would be beneﬁcial. Programs
with the greatest risk of failure should be reserved for
the most grievous illness, novel science, and potential
biggest incremental advance for patients. Last, tech-
nological advances in small and large molecule gen-
eration andmanufacturing as well as new insights into
biology that allow for different therapeutic modal-
ities have positioned the industry to address cardio-
vascular disease in ways previously not achievable.
From a “Big Pharma” industry perspective, simple
randomized trial design could prove to be key. This
pathway emphasizes clinical outcomes over putative
surrogate endpoints. Trials must be sufﬁciently large
to detect small but clinically-meaningful differences
in mortality and other major outcomes important to
both the individual and to society. Priority should be
given to suspected unexpected serious adverse re-
actions and to limiting the recording of less impactful
adverse and serious adverse events. Streamlined,
risk-based, and remote monitoring would be beneﬁ-
cial. Big ﬁrms should continue to strive to improve
trial efﬁciency and emphasize meaningful clinical
outcomes.
PROMISING TRIAL DESIGNS TO IMPROVE DRUG
DEVELOPMENT. A potential novel strategy to help
streamline clinical trials in the future would be to
perform a smaller pre-marketing study but agree to a
larger post-marketing comparative effectiveness trial.
Currently, post-marketing studies cannot be used to
support approval and are primarily used to reﬁne the
labeling of an approved drug therapy. These are
generally studies required of or agreed to by a
sponsor that are conducted after the FDA has
approved a product for marketing, and they typically
serve to gather additional information about a prod-
uct’s safety, efﬁcacy, or optimal use (98). By func-
tioning as a more comprehensive extension of a
typical post-marketing study, a “continuum” studydesign would pre-specify integrated, systematic,
monitored data from pooled pre-market randomized
and post-market registry (99). Gathering pre- and
post-market “real world” safety data might both
improve safety assessment and support the assurance
of safety in smaller pre-market studies. From an in-
dustry perspective, smaller studies resulting in
reduction of pre-market cost and time could provide
incentive for a serious commitment to complete post-
market registries that are larger and more rigorous
than current post-market data collections. In 2012,
the FDA released its vision for post-market surveil-
lance for medical devices (100). Although this effort
speciﬁcally covered medical devices, this system
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1580could be adapted and implemented as a form of post-
market enforcement to study novel drugs. These
systems can and should be used to also assess efﬁcacy
(101). Furthermore, such post-marketing comparative
effectiveness trials could align with 1 of several
Patient-Centered Outcomes Research Institute initia-
tives, including PCORnet (discussed previously),
whose goal is to build clinical research into the health
care process by creating a national network for con-
ducting clinical outcomes research (102,103). An ex-
ample of a future clinical trial integrating an industry
sponsor, the FDA, and patient-centered outcomes
might be a post-marketing comparative effectiveness
trial supported by the Patient-Centered Outcomes
Research Institute, the data from which are then
captured, integrated, and studied using PCORnet.
CONCLUSIONS: A CALL TO END
THE HIBERNATION
Despite the growing global burden of cardiovascular
disease, metrics indicate that cardiovascular drug
development has steadily declined relative to the
growth of scientiﬁc discovery and the expansion of
development in other therapeutic areas. This trend is
particularly concerning given the unprecedented ef-
fect of cardiovascular drugs on outcomes, particularly
in high-income countries (104). Investment in car-
diovascular drug development has shifted elsewhere.
This trend seems driven primarily by economic fac-
tors, including ROI with increased reimbursement
and the perceived reduction in investment risk in
bringing noncardiovascular drugs to market.
Nevertheless, the science of clinical therapeutics
drives the continued requirement for the ﬁeld of car-
diovascular medicine to have large cardiovascular
outcomes trials to demonstrate the balance of beneﬁts
and harms of potential novel therapies. Fortunately,despite the current perceived hibernation of cardio-
vascular drug development, most large pharmaceu-
tical ﬁrms still have an interest in pursuing novel
cardiovascular therapies should the right opportunity
exist (45). The key issues and potential solutions are
summarized in Table 2. Leveraging academic collabo-
rations and novel governmental programs to identify,
derisk, and develop potential therapeutic targets
through pre-clinical and early-phase development
appears to provide a positive path forward. By
strengthening and reﬁning the scientiﬁc questions and
early-phase discoveries, cardiovascular drug devel-
opment can rise once again by targeting enriched
populations, using novel operational approaches to
study design and conduct afforded by advances in the
science of clinical trials, and emphasizing the pursuit
of unmet clinical needs. Outcomes research and pop-
ulation health are coalescing around streamlining and
simpliﬁcation. As such, the “hibernation period” for
cardiovascular drug development could draw to a close
by application of the principles recommended in this
paper.
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